Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: June 7, 2008
Last updated: December 13, 2009
Last verified: July 2009

RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is evaluating kidney damage in patients receiving cisplatin and ifosfamide for solid tumors.

Condition Intervention
Chemotherapeutic Agent Toxicity
Renal Toxicity
Unspecified Adult Solid Tumor, Protocol Specific
Drug: cisplatin
Drug: ifosfamide
Other: laboratory biomarker analysis

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Evolution of different biomarkers [ Designated as safety issue: No ]
  • Sensitivity, specificity, and predictive value (positive and negative) of different markers [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: October 2007
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Detailed Description:



  • Identify and evaluate the early biomarkers of renal toxicity in patients with solid tumors treated with cisplatin and ifosfamide.


  • Correlate the modification of biomarker studies and blood concentrations of cisplatin.

OUTLINE: Patients receive standard chemotherapy comprising cisplatin and/or ifosfamide.

Blood and urine samples are collected on days 1 and 2 (or day 3 if receiving ifosfamide only) during the first 3 courses. Samples are analyzed to determine plasma concentrations of residual cisplatin and to obtain urinary-protein profiles to measure renal toxicity.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Diagnosis of a solid tumor

    • Any location allowed
    • Metastatic disease allowed
  • Planned treatment comprising cisplatin and/or ifosfamide as standard chemotherapy


Inclusion criteria:

  • Life expectancy > 3 months
  • Creatinine clearance ≥ 60 mL/min
  • Must be available for follow up
  • Not pregnant or nursing
  • Not under guardianship or in prison

Exclusion criteria:

  • Prior drug-related nephrotoxicity
  • Acute, uncontrolled urinary infection or > 48-hours
  • Pre-existing hemorrhagic cystitis
  • Weak bladder
  • Bilateral obstruction of urinary tract
  • Insufficient, severe bone marrow hypoplasia
  • Cardiorespiratory condition contraindicating hyperhydration
  • Hearing impairment
  • Hypersensitivity to cisplatin or products containing platinum
  • Major psychiatric condition (severe depression, psychosis, dementia)


  • No prior yellow fever vaccine, live attenuated vaccine, or phenytoin
  • No concurrent participation in another biomedical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00695032

Institut Claudius Regaud Recruiting
Toulouse, France, 31052
Contact: Contact Person    33-5-6142-4114      
Sponsors and Collaborators
Institut Claudius Regaud
Study Chair: Christine Chevreau-Dalbianco, MD Institut Claudius Regaud
  More Information

Additional Information:
No publications provided Identifier: NCT00695032     History of Changes
Other Study ID Numbers: CDR0000589590, ICREGAUD-TOXIPLAT, ICREGAUD-07-GENE-03, EUDRACT-2007-004251-12, INCA-RECF0479
Study First Received: June 7, 2008
Last Updated: December 13, 2009
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
renal toxicity
chemotherapeutic agent toxicity
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Isophosphamide mustard
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on October 21, 2014